Bimatoprost SR for Glaucoma Therapy Implanted at the Slit-Lamp in a Real-World Setting

Figures & data

Table 1 Demographics and Baseline Glaucoma Data

Parameter	Value
Subject-level (N=81)
Age (yr), mean (SD)	73.7 (11.5)
Sex, n (%)
Male	20 (24.7)
Female	61 (75.3)
Ethnicity, n (%)
Caucasian	61 (75.3)
Black	11 (13.6)
Hispanic	4 (4.9)
Other	5 (6.2)
Eye-level (N=129)
Glaucoma diagnosis, n (%)
Primary open-angle	111 (86.0)
Normal tension	9 (7.0)
Other	9 (7.0)
Mean (SD) IOP, mmHg	16.0 (4.0)
No. of glaucoma medications at baseline, n (%)
0	11 (8.5)
1	53 (41.1)
2	32 (24.8)
3	26 (20.2)
>3	7 (5.4)
Prior glaucoma procedures, n (%)
Any	69 (53.5)
Laser trabeculoplasty	41 (31.8)
Laser iridotomy	8 (6.2)
Goniotomy (excisional or by ablation)	12 (9.3)
Trabecular micro-bypass implant or canal stent	10 (7.8)
Cilioablation	11 (8.5)
Tube-shunt	5 (3.9)
Trabeculectomy	5 (3.9)
Gel stent	7 (5.4)
Gonioscopy-assisted transluminal trabeculotomy	7 (5.4)
Phakic status, n (%)
Phakic	46 (35.7)
Pseudophakic	83 (64.3)

Figure 1 Kaplan-Meier survival plot of survival to next IOP-lowering intervention. Shaded region represents 95% confidence interval.

Table 2 Intraocular Pressure (IOP) and Medication Data Through 12 Months of Follow-Up.

	Month 1	Month 3	Month 6	Month 9	Month 12
IOP
N	109	80	86	48	26
Baseline IOP, mean (SD)	16.2 (4.1)	16.2 (3.2)	15.4 (3.4)	14.7 (3.7)	14.5 (3.6)
Mean (SD)	16.3 (4.4)	17.4 (5.1)	17.0 (4.9)	15.5 (4.7)	15.7 (4.3)
CFB (SD)	0.2 (3.6)	1.2 (4.2)	1.7 (3.9)	0.8 (3.7)	1.3 (3.5)
P	0.656	0.013	<0.001	0.150	0.047
Medications
N	110	88	101	88	79
Baseline (n-adjusted)	1.8 (1.1)	1.6 (1.0)	1.7 (1.0)	1.7 (0.9)	1.7 (0.9)
Mean (SD)	0.7 (0.9)	0.7 (0.9)	0.8 (1.0)	1.1 (1.0)	1.2 (1.2)
CFB	−1.0	−1.0	−0.9	−0.6	−0.5
P	<0.001	<0.001	<0.001	<0.001	<0.001
Medication-free, n (%)	61 (55.5)	51 (58)	51 (50.5)	24 (27.2)	22 (27.8)

Notes: Because Treatment Failures Received Additional IOP-Lowering Interventions, Only Treatment Successes are Included in the IOP Analysis, and to Account for the Diminishing Sample Size Over Time as Treatment Failures Occur, Baseline IOP Values for Each Post-Treatment Time Point Have Been Adjusted to Include Only Those Eyes Still Deemed Treatment Successes at the Respective Time Points. In Contrast, the Medication Analysis Includes All Eyes Evaluated at Each Time Point Regarding of Success/Failure Status to Reflect the Addition of Medications in Eyes Failing Treatment.

Abbreviations: CFB, change from baseline; SD, standard deviation.